provide an in-depth exploration of key concepts in pharmacology, offering a nuanced understanding of drug interactions

February 2022 "Switzerland Today, InterAx Biotech is pleased to announce that Carola Weiss has joined Carola Weiss is a Senior Executive with more than 20 years of international experience in the biopharmaceutical

February 2022 "InterAx Biotech AG and Boehringer Ingelheim take first steps towards collaborating to unlock orphan targets leveraging InterAx AI driven discovery platform. first-in-class small molecule agonists for a challenging orphan GPCR for a highly relevant therapeutic need. 💊 InterAx Biotech AG discovery platform was already successfully applied in projects with biopharmaceutical companies #ai #biotech #systemsbiology #drugdiscovery #gpcr #deeptech #orphandrugs #pharma #partnerships #AI4drugdiscovery

Joanne Waldstreicher to its Board of Directors GPCR Therapeutics launches multiple myeloma trial Salipro Biotech Japan, organized by LINK-J Jounce takes the cash under amended deal with Gilead on anti-CCR8 antibody InterAx Biotech Announces the Appointment of Seasoned Pharmaceutical Executive, Dr. SLAS2023 International Conference and Exhibition (February 25 - March 1, 2023). 2nd ERNEST Training School

and at the University in Graz in Austria, Maria worked several years at Novo Nordisk before joining InterAx Biotech in Switzerland as their Chief Scientific Officer. Maria Waldhoer on the web LinkedIn InterAx Biotech Pubmed Dr.

He is Chief Scientific Officer and co-founder of InterAx Biotech, where he specializes in the development Aurélien Rizk on the web InterAx Biotech Paul Scherrer Institut The Org LinkedIn Google Scholar Dr.

He is Chief Scientific Officer and co-founder of InterAx Biotech, where he specializes in the development Aurélien Rizk on the web InterAx Biotech Paul Scherrer Institut The Org LinkedIn Google Scholar Dr.